• Press Release

Could Taking a Drug Within a Few Hours of a Trauma Help Avert Post Traumatic Stress Disorder?

Mount Sinai Receives $6 Million Award from United States Department of Defense to Study Oral Hydrocortisone for PTSD Prevention

  • New York, NY
  • (April 25, 2019)

Researchers at the Icahn School of Medicine at Mount Sinai have been awarded nearly $6 million through a U.S. Army Medical Research grant to test whether a one-time dose of a drug—oral hydrocortisone (HCORT)—can prevent post-traumatic stress disorder (PTSD) and related mental health disturbances in both civilians and military personnel.

Oral hydrocortisone is a synthetic glucocorticoid similar to the body’s own cortisol and has numerous clinical uses as an anti-inflammatory agent. In response to acute stress, ample cortisol levels are critical to activating, and then containing, body systems that are mobilized as part of the fight-or-flight response. Previous studies have shown that people with lower cortisol levels at the time of trauma exposure are at elevated risk for PTSD. 

This study, titled “PTSD Prevention Using Oral Hyrdocortisone in the Immediate Aftermath of Trauma,” is based on the hypothesis that a single administration of HCORT within six hours after trauma will facilitate cortisol-induced suppression of adrenaline that might otherwise lead to the “over-consolidation” of traumatic memories implicated in PTSD, therefore leading to quicker and greater recovery.

“Our team has already conducted two trials that provided sound pilot data to support this hypothesis,” says Rachel Yehuda, PhD, Professor of Psychiatry, and Neuroscience, at the Icahn School of Medicine at Mount Sinai, a recognized scientific expert on resilience and Principal Investigator of the study. “If successful, this work could lead to an easily administered, inexpensive, and portable intervention that doesn’t require evaluation of risk or vulnerability prior to or after trauma exposure. This resilience-enhancing intervention would be safe for both men and women, and could be administered to people who would not otherwise develop PTSD without harm or consequence.”

Specifically, this will be a two-site, double-blind, randomized, placebo-controlled trial conducted on 220 recently traumatized patients presenting to the emergency departments of two large hospitals: The Mount Sinai Hospital in New York City, which serves a diverse population of civilians, and Chaim Sheba Medical Center in Israel, which serves both civilians and military personnel. 

Study participants will receive a single oral dose of HCORT or placebo within six hours following their trauma and will be subsequently assessed at 2, 6, 12, and 42 weeks. After ingestion of the HCORT or placebo, blood will be drawn for baseline biological assessment.  Symptoms will be assessed and blood and salivary cortisol samples will be obtained at each subsequent visit. The collection of biological samples at each time point will allow verification of mechanism of action of the HCORT intervention. Biological assessments include plasma cortisol and adrenocorticotrophin hormone, whole blood NR3C1 and FKBP5 gene methylation and expression, salivary circadian rhythm of cortisol, plasma neuropeptide Y, cytokines and immune markers, and sympathetic nervous system activity. 

The particular aims of the study are (1) to determine whether early intervention with a single dose of HCORT will reduce the risk of PTSD in trauma survivors displaying distress in the emergency department, (2) to evaluate whether HCORT alters the trajectory of a range of mental health symptoms including anxiety, depression, dissociation, and disrupted sleep, (3) to determine whether acute hormonal and related molecular responses to trauma predict the development of PTSD (in the placebo condition) or its prevention by HCORT, and (4) to assess biological measures over time in those receiving HCORT versus placebo to establish whether biological changes associated with resilience have occurred. 

“The military has a critical need for a highly portable, easily administered intervention that can attenuate acute symptoms and prevent longer-term mental health consequences following critical incidents,” says Dr. Yehuda. “But if the study shows that rapid HCORT administration helps prevent PTSD, the intervention will dramatically improve patient care for military personnel and civilians by mitigating the impact of trauma.”

This grant supports an international, collaborative study between the Icahn School of Medicine at Mount Sinai and Chaim Sheba Medical School in Israel.  These two academic research institutions have collaborated on previous related studies. 

About the Mount Sinai Health System

The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on FacebookTwitter and YouTube.